Skip to search formSkip to main contentSkip to account menu

JM9

Known as: JM-9 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

iproplatin

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2004
2004
A phase II study of the platinum analogues JM8 and JM9 in malignant pleural mesothelioma
SummaryThe platinum analogues JM8 and JM9 were assigned randomly to 16 patients with pleural mesothelioma. Nine patients received… 
2004
2004
Comparative cytotoxicity between cisplatin and second generation platinum analogs
The cytotoxic activity of cis-DDP and four second generation platinum coordination complexes (TNO-6; JM-82; JM-8; and JM-9) was… 
1993
1993
Trend of isolation and serotypes of group B streptococci in Korea.
Group B streptococci (GBS) neonatal infection, a prevalent disease in western countries, is considered rare in Korea. GBS… 
1992
1992
Quantitative ultrastructural effects of cisplatin (Platinol), carboplatin (JM8), and iproplatin (JM9) on neurons of freshwater snail Lymnaea stagnalis.
Qualitative and quantitative ultrastructural effects of the platinum compounds cisplatin (Platinol), carboplatin (JM8), and… 
1988
1988
[Anti-cancer drug sensitivity test against human testicular cancer xenograft--comparison with clinical results of chemotherapy].
The antitumor effect of vinblastine (VBL), vincristine (VCR), etoposide (VP-16), teniposide (VM-26), cisplatin (CDDP), CBDCA (JM… 
1987
1987
Determination of platinum-containing drugs in human plasma by liquid chromatography with reductive electrochemical detection.
1987
1987
[Second-generation cisplatin analogs].
Since the introduction into clinical practice in 1972, cisplatin (CDDP) has assumed an important role in the treatment of various… 
1986
1986
Ligands of second generation platinum analogs decrease both platinum-induced DNA cross-linking and its ability to interact with 1-beta-D-arabinofuranosyl cytosine to potentiate cytotoxic efficacy.
1984
1984
Initial Clinical Sudies with Iproplatin (CHIP, JM9)
Iproplatin (CHIP, JM9) was given to 21 patients (pts) with advanced solid tumors at doses of 20–350mg/m2 preceded by 2L of 0.5N… 
1982
1982
Characterization of in vitro deoxyribonucleic acid breakage and cross-linking induced by bis-isopropylamine)-trans-dihydroxy-cis-dichloroplatinum(IV).
Bis(isopropylamine)-trans-dihydroxy-cis-dichloroplatinum(IV) (CHIP or JM-9), a derivative of Cisplatin, was found to have DNA… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)